IDXX

AI Memo

IDEXX Laboratories

As of 2026-09-03/Confidence high

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-03 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

high

Horizon

—

Key catalyst

Q2 2026 results and higher FY2026 outlook • 2026-08-04

Base target: $596 / p=55% prob

Biggest risk

The bear case is that U.S. veterinary visit softness, competitive pressure, or cost-conscious care reduce utilization and limit the benefit of new diagnostic placements. The packet does not provide a detailed post-earnings analyst revision set or verified market-reaction attribution.

Invalidation

Break below $480 or thesis failure.

What would change my mind?

The bull case rests on durable recurring CAG Diagnostics growth, increased testing per visit, continued installed-base expansion, and the higher 2026 outlook. Q2 execution provides strong primary-source support, but the forward thesis still depends on sustained utilization and customer adoption.

Research note

Recommendation

—

Confidence

high

As of

2026-09-03

Base target

$596

p=55%

Bull target

$718

p=25%

Bear target

$480

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Recurring diagnostics utilization and installed-base expansion
Execution against raised 2026 guidance
The bull case rests on durable recurring CAG Diagnostics growth, increased testing per visit, continued installed-base expansion, and the higher 2026 outlook.

BearKey bullets

Analyst target count, detailed estimate revisions, options data, short interest, social sentiment, and post-earnings price-reaction attribution are unavailable.
Competition from animal-health companies, veterinary reference laboratories, and corporate hospital networks could pressure execution [#10-K-2026-02-20].
Foreign-exchange estimates already represent a stated $15 million 2026 revenue headwind [#SEC-8K-2026-08-04].

WatchKey bullets

Q2 2026 results and higher FY2026 outlook

Summary

High-level snapshot

Recommendation

Model confidence

high

Timeframe

Asset

Equity

Trigger

Base case: $596 (p=55%)

Target spread vs base: +20% / -19%

Scenario probabilities

Bull Target: $718 (p=25%)Base Target: $596 (p=55%)Bear Target: $480 (p=20%)

Commentary

Recent news flow is earnings-positive, supported by reported growth and a modestly higher 2026 outlook. However, social coverage and analyst-revision data are unavailable, and no verified post-print market-reaction attribution is supplied; confidence is therefore below that of the primary operating evidence.

As of 2026-09-03 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Recurring diagnostics utilization and installed-base expansion
Execution against raised 2026 guidance

Scenarios

Bull Target (Scenario probability)

$718 / p=25% prob

Base Target (Scenario probability)

$596 / p=55% prob

Bear Target (Scenario probability)

$480 / p=20% prob

Analysis 2026-09-03 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.70

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-04
Q2 2026 results and higher FY2026 outlook
IDEXX reported Q2 revenue growth of 10% reported and 9% organic, CAG Diagnostics recurring revenue growth of 11% reported and 10% organic, EPS of $4.27, and raised its 2026 EPS outlook to $14.69-$14.94 while narrowing revenue guidance to $4.700-$4.745 billion [#8-K-2026-08-04] [#SEC-8K-2026-08-04].
Prob 95.00% • Move 4.60% • Priced-in 75.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Recurring diagnostics utilization and installed-base expansion
2026-12-31
Management cited volume-driven recurring diagnostics growth, innovation, and higher utilization; the IDEXX inVue Dx installed base surpassed 9,000 instruments after more than 1,600 quarterly placements [#8-K-2026-08-04].
Prob 78% • Move 12% • Priced-in 55%
Execution against raised 2026 guidance
2026-12-31
The raised midpoint incorporates stronger CAG Diagnostics recurring revenue performance despite a stated $15 million foreign-exchange headwind, creating a dated execution checkpoint through the remainder of 2026 [#8-K-2026-08-04].
Prob 72% • Move 9% • Priced-in 65%

Risks

Analyst target count, detailed estimate revisions, options data, short interest, social sentiment, and post-earnings price-reaction attribution are unavailable.
Competition from animal-health companies, veterinary reference laboratories, and corporate hospital networks could pressure execution [#10-K-2026-02-20].
Foreign-exchange estimates already represent a stated $15 million 2026 revenue headwind [#SEC-8K-2026-08-04].
U.S. veterinary practice visit softness could weaken diagnostic utilization and recurring-growth momentum.

Peers

Symbol	Summary
ZTS	Direct public animal-health and veterinary-diagnostics competitor identified in IDEXX's 2025 Form 10-K; the closest listed operating comparator in the available evidence [#10-K-2026-02-20].

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-03

Loading AI feed…

Symbol

Summary

ZTS

Direct public animal-health and veterinary-diagnostics competitor identified in IDEXX's 2025 Form 10-K; the closest listed operating comparator in the available evidence [#10-K-2026-02-20].